Christi J. van Asperen
克里斯蒂·范阿斯佩伦
MD, PhD
Professor and Clinical Geneticist, Department of Clinical Genetics临床遗传学系教授兼临床遗传学家
👥Biography 个人简介
Prominent Dutch clinical geneticist specializing in hereditary breast and ovarian cancer. Her research on BRCA and moderate-risk gene clinical management has shaped Netherlands national guidelines and contributed to European hereditary cancer surveillance standards.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Dutch BRCA Surveillance Guidelines
Led development of Netherlands national guidelines for surveillance and risk reduction in BRCA1/2 carriers, incorporating MRI screening protocols that have become a model for European hereditary cancer programs.
Moderate-Risk Gene Clinical Integration
Conducted landmark Dutch studies on CHEK2 and ATM pathogenic variants in breast cancer families, establishing the evidence base for clinical management recommendations for moderate-penetrance hereditary breast cancer genes.
Representative Works 代表性著作
CHEK2*1100delC and susceptibility to hereditary breast cancer in the Netherlands
New England Journal of Medicine (2002)
Identified CHEK2*1100delC as a moderate-risk hereditary breast cancer allele with prevalence and risk data informing clinical testing criteria.
Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a nation-wide Dutch study
Breast Cancer Research and Treatment (2015)
Quantified contralateral breast cancer risk in Dutch BRCA carriers to inform prophylactic mastectomy decision-making.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 克里斯蒂·范阿斯佩伦 的研究动态
Follow Christi J. van Asperen's research updates
留下邮箱，当我们发布与 Christi J. van Asperen（Leiden University Medical Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment